ALKS - アルケルメス （Alkermes plc） アルケルメスALKSのチャート
ALKSの企業情報
| symbol | ALKS |
|---|---|
| 会社名 | Alkermes plc （アルケルメス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 アルケルメス(Alkermes plc.)(Alkermes Inc.)は統合されたバイオテクノロジー企業。同社は一般的な慢性疾患の治療のための医薬品の開発、製造と商品化に従事している。同社はアルコール依存症の治療薬｢VIVITROL｣の開発・製造・商品化、及び統合失調症と双極I型障害の治療薬｢RISPERDAL CONSTA｣の製造を行っている。同社の薬品パイプラインは中枢神経系（CNS）疾患、報酬障害、中毒、糖尿病と自己免疫疾患などの一般的な慢性疾患の治療のための徐放性注射剤と経口製品を含む。同社はマサチューセッツ州に１カ所の研究施設、オハイオ州に１カ所の商業生産施設を有している。平成23年9月、同社はアイルランドで事業活動を開始した。平成23年9月16日、同社はElan Corporation plc (Elan)の製剤と薬品製造事業ユニットであるエラン医薬品テクノロジーズ（EDT）と合併した。 アルケルメスはアイルランドのバイオ医薬品会社。依存症、統合失調症、うつ病など中枢神経障害の治療用製品の開発と商業化に従事。製品には統合失調症治療薬｢リスパダ―ル・コンスタ｣、多発性硬化症治療薬｢アムピラ｣、2型糖尿病治療薬徐放性剤｢ビデュリオン｣、アルコ―ル依存症治療薬｢ビビトロル｣などがある。 Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on addiction and schizophrenia, and a pipeline of product candidates in development for schizophrenia, bipolar I disorder, neurodegenerative disorders, and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. |
| 本社所在地 | Connaught House 1 Burlington Road Dublin 02451 IRL |
| 代表者氏名 | Richard F. Pops リチャードF.ポップス |
| 代表者役職名 | Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者 |
| 電話番号 | +353 1-772-8000 |
| 設立年月日 | 31959 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 1991年 |
| 従業員数 | 2000人 |
| url | www.alkermes.com |
| nasdaq_url | https://www.nasdaq.com/symbol/alks |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） 7.23400 |
| 終値（lastsale） | 44.45 |
| 時価総額（marketcap） | 6903759662.1 |
| 時価総額 | 時価総額（百万ドル） 6709.616 |
| 売上高 | 売上高（百万ドル） 122.547 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 6556.5 |
| 当期純利益 | 当期純利益（百万ドル） -119.76600 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Alkermes Plc revenues increased 29% to $529.8M. Net loss decreased 15% to $95.2M. Revenues reflect Product sales net increase of 22% to $201.6M Research and development revenue increase from $1.5M to $37.1M. Lower net loss reflects Interest Income increase of 60% to $3.4M (income). Basic Earnings per Share excluding Extraordinary Items increased from -$0.73 to -$0.61. |
ALKSのテクニカル分析
ALKSのニュース
Alkermes Athlone Receives Award at Ireland’s 2023 Health & Safety Excellence Awards 2023/05/02 17:30:00 Accesswire
NORTHAMPTON, MA / ACCESSWIRE / May 2, 2023 / Alkermes Athlone site recently received a 2023 award in the Life Sciences category at Ireland''s 2023 Health & Safety Excellence Awards. This recognition is a testament to our employees'' focus on building a culture of safety and risk management in Athlone. Learn more about this honor: https://lnkd.in/eHzGMjC About Alkermes Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes'' website at www.alkermes.com .
Alkermes Inspiration Grants Now Open for Applications 2023/05/01 17:30:00 Accesswire
NORTHAMPTON, MA / ACCESSWIRE / May 1, 2023 / The 2023 Alkermes Inspiration Grants® program is now open for applications! These grants are designed to support programs or organizations for people affected by serious mental illness, addiction and cancer. Apply here: https://www.alkermes.com/responsibility/alkermes-inspiration-grants-2023 View additional multimedia and more ESG storytelling from Alkermes on 3blmedia.com. Contact Info: Spokesperson: Alkermes Website: https://www.3blmedia.com/profiles/alkermes Email: info@3blmedia.com SOURCE: Alkermes
Substance Abuse And Addiction Treatment Market Size, Share, Revenue, Trends And Drivers For 2023-2032 As Per The Business Research Company''s Substance Abuse and Addiction Treatment Global Market Report for 2023 2023/05/01 15:30:00 Benzinga
LONDON, May 01, 2023 (GLOBE NEWSWIRE) -- The Business Research Company''s research on the substance abuse and addiction treatment market forecasts the market to experience significant growth, increasing from $9.8 billion in 2022 to $10.9 billion in 2023 at a CAGR of more than 11%. Furthermore, global market for substance abuse and addiction treatment size is expected to reach $15.8 billion in 2027 at a CAGR of more than 9% . This growth can be attributed to the high prevalence of alcohol use , which has led to an increase in the number of individuals seeking treatment. North America was the largest region in the substance abuse and addiction market in 2022.In August 2022, data published by RTI International, a US bases non-profit organization, indicated that alcohol consumption in November 2020 was 39% higher than in February 2020. Additionally, binge drinking increased by 26% between February and April 2020 and by 30% between February and November 2020. This high prevalence of alcohol use is driving the growth of the substance abuse and addiction treatment market.
Alkermes plc (ALKS) Q1 2023 Earnings Call Transcript 2023/04/26 21:05:18 Seeking Alpha
Alkermes plc (NASDAQ:NASDAQ:ALKS) Q1 2023 Earnings Conference Call April 26, 2023 8:00 AM ETCompany ParticipantsSandra Coombs - Senior Vice President of Investor Relations and Corporate…
Alkermes: Clinical Trials Integral to Providing More Treatment Options for Platinum-Resistant Ovarian Cancer 2023/04/26 17:26:00 Finanz Nachrichten
NORTHAMPTON, MA / ACCESSWIRE / April 26, 2023 / Patients diagnosed with platinum-resistant Ovarian Cancer (PROC) often face poor prognosis due to the limited treatment options. Watch this video to …
Alkermes Celebrates Employee Volunteerism Throughout 2022 2023/02/02 19:15:00 Wallstreet:Online
NORTHAMPTON, MA / ACCESSWIRE / February 2, 2023 / Alkermes is committed to improving the communities where we live and work. Check out this video to see some highlights of our employees'' volunteer work in 2022!View additional multimedia and more ESG …
How Is the Brain Affected by Alcohol? 2023/01/31 21:05:00 Accesswire
NORTHAMPTON, MA / ACCESSWIRE / January 31, 2023 / Alkermes As Dry January comes to an end, learn more about how alcohol dependence affects the brain in this animation. Also, if you have concerns about your drinking habits, this questionnaire may be of help: https://lnkd.in/e3wwmTKK View additional multimedia and more ESG storytelling from Alkermes on 3blmedia.com. Contact Info: Spokesperson: Alkermes Website: https://www.3blmedia.com/profiles/alkermes Email: info@3blmedia.com SOURCE: Alkermes
These strategies will help Alkermes plc (ALKS) succeed 2023/01/27 16:48:00 US Post News
Alkermes plc (NASDAQ:ALKS) closed Thursday at $28.50 per share, up from $28.34 a day earlier. While Alkermes plc has overperformed by 0.56%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ALKS rose by 13.14%, with highs and lows ranging from $32.79 to $21.75, whereas the simple […]
Alkermes PT Raised to $42 at Jefferies 2023/01/17 19:32:04 Investing.com
https://www.investing.com/news/pro/alkermes-pt-raised-to-42-at-jefferies-432SI-2982164
Alkermes: Nemvaleukin Alfa Gets UK MHRA''s Innovation Passport Designation To Treat Mucosal Melanoma 2023/01/17 12:36:00 Finanz Nachrichten
LONDON (dpa-AFX) - Irish biopharmaceutical company Alkermes plc (ALKS) announced Tuesday that UK regulatory body, the Medicines and Healthcare products Regulatory Agency or MHRA, has granted an In…
Alkermes: 47% of Adults With Alcohol Use Disorder Sought Help Because of Family Encouragement 2022/12/08 19:32:00 Finanz Nachrichten
NORTHAMPTON, MA / ACCESSWIRE / December 8, 2022 / Alkermes:For some people living with alcohol dependence, families play a support role. In fact, 47% of adults who sought treatment did so because a…
47% of Adults With Alcohol Use Disorder Sought Help Because of Family Encouragement 2022/12/08 19:30:00 Accesswire
NORTHAMPTON, MA / ACCESSWIRE / December 8, 2022 / Alkermes: For some people living with alcohol dependence, families play a support role. In fact, 47% of adults who sought treatment did so because a family member expressed concern. If someone you know is living with alcohol dependence, your support matters. Learn more here . View additional multimedia and more ESG storytelling from Alkermes on 3blmedia.com. Contact Info: Spokesperson: Alkermes Website: http://www.alkermes.com/ Email: info@3blmedia.com SOURCE: Alkermes
Patient Advocacy at Alkermes 2022/12/06 19:00:00 Accesswire
NORTHAMPTON, MA / ACCESSWIRE / December 6, 2022 / Alkermes Originally published in Alkermes 2021 Corporate Responsibility We have developed and now manufacture and commercialize proprietary medicines for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder - disease areas with vulnerable patient populations who are often treated in public health and criminal justice settings where systemic inequities are pervasive. We champion approaches to treatment that recognize the multitude of factors that affect outcomes for patients, caregivers and communities, and are committed to patient and community engagement, disease education and awareness and advocacy for policies that support equitable access to treatment options. Patient advocacy and community engagement are core to our mission. Regular engagements with policymakers and leaders in the patient advocacy community allow us to better understand their perspectives and goals. Learnings from these interactions help to inform our business activities, including in respect to clinical trials, policy and advocacy.
Alkermes Celebrates Giving Tuesday With Volunteering Efforts 2022/12/01 19:55:00 Accesswire
NORTHAMPTON, MA / ACCESSWIRE / December 1, 2022 / This Giving Tuesday, we are thankful for the employees who take time to support people in our communities who are in need. 10+ years ago, we launched Alkermes in Action, an annual employee volunteer program designed to support volunteer efforts in the places we live and work. We were also grateful to have the opportunity to support organizations that share our goals related to diversity, inclusion and belonging. In 2022, this included NAACP, OUTbio, Wreaths Across America and 500 Women Scientists, among other organizations, all of which are doing important work to make our communities more inclusive. To learn more about our diversity, inclusion and belonging work, check out: https://www.alkermes.com/ View additional multimedia and more ESG storytelling from Alkermes on 3blmedia.com. Contact Info: Spokesperson: Alkermes Website: http://www.alkermes.com/ Email: info@3blmedia.com SOURCE: Alkermes
Alkermes plc: Alkermes to Participate in the BofA Securities 2022 Biotech SMID Cap Conference 2022/11/30 21:04:00 Finanz Nachrichten
DUBLIN, Nov. 30, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat as part of the BofA Securities 2022 Biotech SMID Cap Conferenc…